ANRO at a glance
The past year
Chart+79.7% $26.51, close Nov 19
- From the highest close
- −27.6%
- Vs the 200-day average
- +6.3%
Short interest
History5.7M shares
- Of shares outstanding
- 14.2%
- Since the last report
- +9.2%
- Days to cover
- 11 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 13 – Nov 19
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
ANRO price history
Loading recent earnings…
Investment thesis
What must happen next
Alto’s core edge depends on neurobiology-based patient selection translating into better clinical efficacy than conventional psychiatry development; if biomarkers do not enrich responders, the company has little durable differentiation.HoldingMateriality: High
The company describes itself as a clinical-stage biopharmaceutical company seeking to redefine psychiatry by leveraging neurobiology to develop personalized treatment options. If it holds, Alto’s pipeline can deserve a higher probability of success; if it breaks, the equity becomes a generic high-risk CNS biotech.
Watch: A biomarker-selected trial fails to show a clinically meaningful separation from control or non-selected patient approaches.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company describes itself as a clinical-stage biopharmaceutical company seeking to redefine psychiatry by leveraging neurobiology to develop personalized treatment.
Open source ↗The business model only has value if Alto’s cash balance can fund the next decisive clinical milestones without forcing distressed financing.StrengtheningMateriality: High
GAAP cash was $176.5 million at fiscal year-end 2025. Adequate runway lets clinical data determine value; inadequate runway shifts value from existing holders to new capital providers.
Watch: Alto initiates larger or additional later-stage trials before securing partner funding, materially increasing burn ahead of data.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP cash was $176.5 million at fiscal year-end 2025.
Open source ↗Alto must keep its R&D and corporate spending tied to value-creating clinical milestones rather than building an expensive fixed-cost base before proof of efficacy.HoldingMateriality: Medium
Annual GAAP operating cash flow was negative $51.8 million in FY2025 versus negative $47.4 million in FY2024, showing higher but not explosive cash use. Disciplined burn preserves option value per share; uncontrolled burn can destroy upside even if the science remains plausible.
Watch: Management commits to multiple large trials simultaneously without corresponding clinical validation or non-dilutive funding.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Annual GAAP operating cash flow was negative $51.8 million in FY2025 versus negative $47.4 million in FY2024, showing higher but.
Open source ↗Low balance-sheet leverage must preserve Alto’s strategic flexibility so clinical upside accrues primarily to equity holders rather than creditors or obligation-heavy counterparties.StrengtheningMateriality: Medium
GAAP liabilities were $33.5 million at fiscal year-end 2025 against GAAP assets of $184.7 million. A clean balance sheet improves negotiating power; rising obligations can cap shareholder upside before the pipeline is proven.
Watch: Alto takes on debt, royalty financing, or expensive licensing obligations to fund trials after weak capital-market access.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP liabilities were $33.5 million at fiscal year-end 2025 against GAAP assets of $184.7 million.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Alto’s core edge depends on neurobiology-based patient selection translating into better clinical efficacy than conventional psychiatry development; if biomarkers do not enrich responders, the company has little durable differentiation. If it holds, Alto’s pipeline can deserve a higher probability of success; if it breaks, the equity becomes a generic high-risk CNS biotech.
The business model only has value if Alto’s cash balance can fund the next decisive clinical milestones without forcing distressed financing. Adequate runway lets clinical data determine value; inadequate runway shifts value from existing holders to new capital providers.
Alto must keep its R&D and corporate spending tied to value-creating clinical milestones rather than building an expensive fixed-cost base before proof of efficacy. Disciplined burn preserves option value per share; uncontrolled burn can destroy upside even if the science remains plausible.
Low balance-sheet leverage must preserve Alto’s strategic flexibility so clinical upside accrues primarily to equity holders rather than creditors or obligation-heavy counterparties. A clean balance sheet improves negotiating power; rising obligations can cap shareholder upside before the pipeline is proven.
All standing thesis claims
Original report summary
its neurobiology-based personalization improves clinical-trial odds before cash burn forces unfavorable dilution.
Bull case and bear case
Bull case and bear case for Alto Neuroscience
Where the evidence on Alto Neuroscience stands: Holding on the latest evidence (Oct 15, 2026). Of its 4 thesis points, 2 strengthening and 2 holding.
Bull case: what the evidence supports
Alto’s core edge depends on neurobiology-based patient selection translating into better clinical efficacy than conventional psychiatry development; if biomarkers do not enrich responders, the company has little durable differentiation.
The business model only has value if Alto’s cash balance can fund the next decisive clinical milestones without forcing distressed financing.
Alto must keep its R&D and corporate spending tied to value-creating clinical milestones rather than building an expensive fixed-cost base before proof of efficacy.
Low balance-sheet leverage must preserve Alto’s strategic flexibility so clinical upside accrues primarily to equity holders rather than creditors or obligation-heavy counterparties.
Bear case: what would count against it
A biomarker-selected trial fails to show a clinically meaningful separation from control or non-selected patient approaches.
Alto initiates larger or additional later-stage trials before securing partner funding, materially increasing burn ahead of data.
Management commits to multiple large trials simultaneously without corresponding clinical validation or non-dilutive funding.
Thesis-Break Engine
What has broken in Alto Neuroscience’s thesis
Each break OptimistFi flagged on Alto Neuroscience, dated — with what has historically followed the same kind of break across the market, not a forecast for Alto Neuroscience.
- Sharp drawdowncondition set before this filing
Across all companies, this kind of break has happened 15,428 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.
- CEO / officer changecondition set before this filing
Across all companies, this kind of break has happened 16,849 times before. Those stocks trailed comparable companies by a median of 2% over the next six months, and 38% of them trailed it by 10 points or more.
- Price target fell below the stockcondition set before this filing
Across all companies, this kind of break has happened 1,809 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.
Several kinds of break have stacked on Alto Neuroscience at once. A cluster is a stronger read than any one signal alone.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedDirector or principal officer change.
Alto Neuroscience filed an SEC 8-K on 2026-08-27: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Alto Neuroscience filed an SEC 8-K on 2026-08-12: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Alto Neuroscience filed an SEC 8-K on 2026-07-14: Entered a material definitive agreement. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A biomarker-selected trial fails to show a clinically meaningful separation from control or non-selected patient approaches.
- Alto initiates larger or additional later-stage trials before securing partner funding, materially increasing burn ahead of data.
- Management commits to multiple large trials simultaneously without corresponding clinical validation or non-dilutive funding.
- Alto takes on debt, royalty financing, or expensive licensing obligations to fund trials after weak capital-market access.
ANRO news
Loading headlines…
Financial statements
ANRO income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
ANRO: quick answers
- When does Alto Neuroscience (ANRO) report earnings next?
- Alto Neuroscience's next results are projected for February 9, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 10, 2026. Earnings calendar
- What is ANRO's short interest?
- As of October 30, 2026, 5.7M ANRO shares were sold short, 14.2% of its shares outstanding, up 9.2% from the count before. At the stock's average daily volume that is 11 days to cover. FINRA publishes the count twice a month. ANRO short interest history

